A Pilot Investigation of Pain Reprocessing Therapy for Functional Dyspepsia
The purpose of this research is to test whether pain processing therapy, a novel psychological intervention that emphasizes exposure-based techniques, can reduce digestive symptom severity and improve functioning in people with functional dyspepsia.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Jonah Pedelty
- 电话号码:507-538-7774
- 邮箱:Pedelty.Jonah@mayo.edu
学习地点
-
-
Minnesota
-
Rochester、Minnesota、美国、55905
- 招聘中
- Mayo Clinic
-
接触:
- Jonah Pedelty
- 电话号码:507-538-7774
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Fulfilled Rome V diagnostic criteria for functional dyspepsia postprandial distress syndrome subtype, with or without epigastric pain syndrome.
- A total score of at least 3 on the Gastroparesis Cardinal Symptom Index (GCSI) indicating symptom severity to be moderate or higher.
- Normal gastric emptying as confirmed by standard gastric emptying testing (if such a testing was clinically done).
- Upper endoscopy negative to rule out structural or organic etiologies for GI symptoms (within last 1 year).
- Fluent in English language.
- Able to provide informed consent and comply with study procedures.
Exclusion Criteria:
- Evidence of organic gastrointestinal disease or surgical history that could explain participant symptoms (e.g., peptic ulcer disease, celiac disease, inflammatory bowel disease, eosinophilic gastritis or eosinophilic esophagitis, malignancy).
- Current or recent (within the past 12 months) eating disorder such as anorexia nervosa or bulimia nervosa. Historical eating disorder diagnosis may also be exclusionary if residual disordered eating patterns, fear of weight gain, or food-related body image concerns are judged by the investigator to potentially confound symptom interpretation or participation.
- Underweight BMI (<17 kg/m²) or evidence of clinically significant unintentional weight loss (>25% body weight in 6 months).
- Current use of enteral or parenteral nutrition for >50% of caloric needs and/or participant unwillingness to reduce use of enteral or parenteral nutrition at the time of study enrollment.
- History of developmental or intellectual disability, current cognitive impairment that would preclude participation, or other neurological illness impairing cognitive functioning.
- Active suicidal ideation, suicide attempt within the past 12 months, severe psychiatric illness, severe depressive symptomatology, acute distress, or other symptomatology that, in the investigator's judgment, would necessitate a different level of psychiatric care and/or prevent full engagement in psychological intervention sessions or adherence to study procedures.
- Medical disability or any unstable systemic illness (e.g., decompensated hepatic, cardiac, renal, or neurological disease) that could interfere with participation, comprehension, or safety in psychological intervention sessions.
- Current daily cannabis use (inhaled, edible, or medical). Other substance use or misuse of prescription medications may also be exclusionary if substance use patterns are judged by the investigator to potentially confound symptom interpretation or participation.
- Current pregnancy or lactation.
- Inability or unwillingness of individual to give informed consent.
- Non-fluent in English, or any condition that would limit compliance or follow-up.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Pain Reprocessing Therapy
Participants will receive eight weekly pain reprocessing therapy sessions. Session 1 will occur at Week 0, and sessions will continue weekly through Session 8 at Week 7. The first and last sessions will be delivered in person when possible to coordinate with baseline and post-treatment physiologic testing, and interim sessions will be completed via telehealth. |
Pain reprocessing therapy is a psychological intervention designed to help patients reconceptualize chronic symptoms in functional dyspepsia as related to changes in brain-gut communication. Treatment includes education about the neuroscience of chronic symptoms, development of a personalized understanding of symptom mechanisms, interoceptive exposure using mindfulness and safety reappraisal, approaches to reduce symptom-related fear and avoidance, techniques for addressing psychosocial threat factors, and strategies to increase positive emotional experiences. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Average Gastroparesis Cardinal Symptom Index Score
大体时间:Baseline, Week 7
|
Change in average Gastroparesis Cardinal Symptom Index score from the Patient Assessment of Upper Gastrointestinal Disorders Symptoms Questionnaire will be assessed. The Gastroparesis Cardinal Symptom Index assesses upper gastrointestinal symptom severity; higher scores indicate greater symptom severity. |
Baseline, Week 7
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Maximum Tolerated Volume During Nutrient Drink Test
大体时间:Baseline, Week 7
|
Change in maximum tolerated volume consumed during the nutrient drink test will be assessed. Maximum tolerated volume is the total volume of nutrient drink consumed before the participant reaches the protocol-defined stopping point. |
Baseline, Week 7
|
|
Change in Symptom Ratings During Nutrient Drink Test
大体时间:Baseline, Week 7
|
Change in standardized symptom ratings collected during the nutrient drink test will be assessed. Symptoms may include fullness, nausea, bloating, and abdominal pain, with higher scores indicating greater symptom severity. |
Baseline, Week 7
|
|
Change in Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life Score
大体时间:Baseline, Week 7
|
Change in Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life score will be assessed. The questionnaire measures disease-specific quality of life in participants with upper gastrointestinal disorders; higher scores indicate better quality of life. |
Baseline, Week 7
|
|
Mean Change From Baseline in Gastrointestinal Unhelpful Thinking Scale Pain Catastrophizing Subscale Score
大体时间:Baseline, Week 7
|
Gastrointestinal-specific pain catastrophizing will be assessed using the Pain Catastrophizing subscale of the Gastrointestinal Unhelpful Thinking Scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in gastrointestinal-specific pain catastrophizing. |
Baseline, Week 7
|
|
Mean Change From Baseline in Visceral Sensitivity Index Score
大体时间:Baseline, Week 7
|
Gastrointestinal-specific anxiety will be assessed using the Visceral Sensitivity Index. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in gastrointestinal-specific anxiety. |
Baseline, Week 7
|
|
Mean Change From Baseline in Fear of Food Questionnaire Score
大体时间:Baseline, Week 7
|
Food-related fear and avoidance will be assessed using the Fear of Food Questionnaire. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in food-related fear and avoidance. |
Baseline, Week 7
|
|
Mean Change From Baseline in Nine Item ARFID Screen Fear Subscale Score
大体时间:Baseline, Week 7
|
Restrictive eating behaviors related to fear of aversive consequences will be assessed using the fear subscale of the Nine Item ARFID Screen. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in fear-related restrictive eating behaviors. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Physical Function Score
大体时间:Baseline, Week 7
|
General physical function will be assessed using the PROMIS Physical Function scale. Mean scores will be calculated at baseline and following completion of treatment. A positive change from baseline indicates improvement in physical function. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Anxiety Score
大体时间:Baseline, Week 7
|
Anxiety will be assessed using the PROMIS Anxiety scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in anxiety. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Depression Score
大体时间:Baseline, Week 7
|
Depression will be assessed using the PROMIS Depression scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in depression. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Fatigue Score
大体时间:Baseline, Week 7
|
Fatigue will be assessed using the PROMIS Fatigue scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in fatigue. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Sleep Disturbance Score
大体时间:Baseline, Week 7
|
Sleep disturbance will be assessed using the PROMIS Sleep Disturbance scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in sleep disturbance. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Ability to Participate in Social Roles and Activities Score
大体时间:Baseline, Week 7
|
Ability to participate in social roles and activities will be assessed using the PROMIS Ability to Participate in Social Roles and Activities scale. Mean scores will be calculated at baseline and following completion of treatment. A positive change from baseline indicates improvement in social participation. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Pain Interference Score
大体时间:Baseline, Week 7
|
Pain interference will be assessed using the PROMIS Pain Interference scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in pain interference. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Pain Intensity Score
大体时间:Baseline, Week 7
|
Pain intensity will be assessed using the PROMIS Pain Intensity numerical rating scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in pain intensity. |
Baseline, Week 7
|
|
Mean Change From Baseline in PROMIS Anger Score
大体时间:Baseline, Week 7
|
Anger will be assessed using the PROMIS Anger scale. Mean scores will be calculated at baseline and following completion of treatment. A negative change from baseline indicates improvement in anger. |
Baseline, Week 7
|
|
Percentage of Participants Who Complete the Pain Reprocessing Therapy Intervention
大体时间:Baseline, Week 7
|
The percentage of enrolled participants who complete all 8 planned pain reprocessing therapy sessions will be reported. |
Baseline, Week 7
|
|
Percentage of Participants Who Report Satisfaction With Pain Reprocessing Therapy
大体时间:Week 7
|
The percentage of participants who rate satisfaction with services as "mostly satisfied" or "very satisfied" on the Client Satisfaction Questionnaire-4 will be reported. |
Week 7
|
合作者和调查者
赞助
调查人员
- 首席研究员:Megan Petrick, PhD、Mayo Clinic
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- 26-003631
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.